BioTuesdays

Tag - INMB

INmune Bio

HCW starts INmune Bio at buy; PT $11.50

H.C. Wainwright launched coverage of INmune Bio with a “buy” rating and price target of $11.50. The stock closed at $5.94 on Aug. 20. INmune Bio is an immunology company developing therapies targeting innate immunity to...

INmune Bio

Maxim starts INmune Bio at buy; PT $13

Maxim Group launched coverage of INmune Bio (NASDAQ:INMB) with a “buy” rating and $13 price target. The stock closed at $7.73 on March 18. INmune Bio is a clinical-stage immunotherapy company with three drug programs...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.